Nice | Rivaroxaban for DVT treatment

21st August 2012 by Louise Hudman

This guideline advises that Rivaroxaban can now be considered for use in the treatment of proximal DVT. It is as effective as warfarin, but is more expensive. I suspect we will need to await local approval before use. It doesn’t require monitoring.

It is contraindicated with GFR < 30 and ‘very high blood pressure’ among other things. Use is normally for 3m, though may be needed for longer if there are ongoing risk factors for VTE. It hasn’t really been studied beyond 12m, so use beyond that is of uncertain effectiveness (though is allowed).

Interestingly, there is a higher risk of non-major bleeding with rivaroxaban than on warfarin, though a similar rate of major bleeding.

Read for free

Sign up to access everything.

Free trial


Already a member? Login to view this content.


"I have been a member of the NASGP for about 18 months and find the support and advice invaluable.

It was especially helpful when I started locum work. I think I must have spent hours on the website devouring every single article as I was keen to learn all I could before I went solo. "

Dr Sally Watkins

Dr Sally Watkins

See the full list of features within our NASGP membership plans